Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Oncology

• Publication date

  2010-11-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO_00000844PMID 21109946
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular endothelial growth factor receptor‐1 in human cancer

  2010cited by this paper
• Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis.

  2009cited by this paper
• NFκB inhibitors: Strategies from poxviruses

  2009cited by this paper
• NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.

  2009cited by this paper
• Recent approaches to improve the antitumor efficacy of temozolomide.

  2009cited by this paper
• Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases

  2008cited by this paper
• Role of mismatch repair and MGMT in response to anticancer therapies.

  2008cited by this paper
• Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues.

  2008cited by this paper
• FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

  2008cited by this paper
• Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

  2007cited by this paper
• Management of metastatic melanoma.

  2007cited by this paper
• Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma.

  2007cited by this paper
• Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents.

  2007cited by this paper
• The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma

  2006cited by this paper
• Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

  2006cited by this paper
• VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease.

  2006cited by this paper
• Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

  2006cited by this paper
• DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.

  2006cited by this paper
• DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells

  2006cited by this paper
• N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor-κB DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity

  2005cited by this paper
• An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.

  2005cited by this paper
• IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

  2005cited by this paper
• Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.

  2004cited by this paper
• To be, or not to be: NF-κB is the answer – role of Rel/NF-κB in the regulation of apoptosis

  2004cited by this paper
• The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer.

  2004cited by this paper
• Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

  2003cited by this paper
• To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis.

  2003cited by this paper
• The Effect of O 6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and Cisplatin

  2003cited by this paper
• Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C.

  2003cited by this paper
• Systemic chemotherapy for the treatment of metastatic melanoma.

  2002cited by this paper
• Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.

  2002cited by this paper
• Placental growth factor is a survival factor for tumor endothelial cells and macrophages.

  2002cited by this paper
• Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

  2000cited by this paper
• Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR

  1999cited by this paper
• O (6)-Alkylguanine-DNA Alkyltransferase Assay.

  1999cited by this paper
• Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

  1997cited by this paper
• Systemic chemotherapy for the treatment of metastatic melanoma.

  1996cited by this paper
• Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

  1989cited by this paper
• Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones.

  1987cited by this paper

• The Role of Placental Growth Factor (PlGF) as a Biomarker in Patients with Resectable Gastric Cancer.

  2025cites this paper
• VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives.

  2024cites this paper
• Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

  2020cites this paper
• Nongenetic Mechanisms of Drug Resistance in Melanoma

  2020cites this paper
• Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages.

  2020cites this paper
• Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib

  2019cites this paper
• Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression

  2019cites this paper
• Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.

  2018cites this paper
• Targeting Chemotherapy Resistance in Glioblastoma Through Modulation of ABC Transporters

  2016cites this paper
• NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization.

  2016cites this paper
• Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.

  2016cites this paper
• Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

  2016cites this paper
• Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment.

  2015cites this paper
• Neuropilin-1 as Therapeutic Target for Malignant Melanoma

  2015cites this paper
• Placental growth factor in cancer

  2014cites this paper
• A20 expressing tumors and anticancer drug resistance.

  2014cites this paper
• Treating malignant glioma in Chinese patients: update on temozolomide

  2014cites this paper
• Etude des mécanismes moléculaires de chimiorésistance du mélanome malin aux vinca-alcaloïdes et aux inhibiteurs de kinases par une approche transcriptomique

  2014cites this paper
• The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis.

  2013cites this paper
• Enhancement of PLGF production by 15-(S)-HETE via PI3K-Akt, NF-κB and COX-2 pathways in rheumatoid arthritis synovial fibroblast.

  2013cites this paper
• Induction of the Unfolded Protein Response Drives Enhanced Metabolism and Chemoresistance in Glioma Cells

  2013cites this paper
• Challenging resistance mechanisms to therapies for metastatic melanoma.

  2013cites this paper
• Improving drug penetration to curb tumor drug resistance.

  2012cites this paper
• The complex interplay between autophagy and NF-κB signaling pathways in cancer cells.

  2011cites this paper
• Minutes of the ESPCR 2010 Board of Officers Meeting , Library of the Hinxton Welcome Trust Conference

  year unknowncites this paper